SMARCA4 and neoplasm: Pathways upregulated and downregulated only in the setting of Cmp14 treatment and not dBRD9-A included those of differentiation and restoration of P53/senescence targets (upregulated), SMARCA4 targets (downregulated) and multicancer invasiveness (downregulated), in line with the greater anti-tumor impact observed with ATPase inhibition relative to dBRD9-A in vivo (Fig. 7D, Extended Data Fig. 7F-G).